vs
FENNEC PHARMACEUTICALS INC.（FENC）与FrontView REIT, Inc.（FVR）财务数据对比。点击上方公司名可切换其他公司
FrontView REIT, Inc.的季度营收约是FENNEC PHARMACEUTICALS INC.的1.3倍（$18.2M vs $13.8M），FrontView REIT, Inc.净利率更高（2.2% vs -34.7%，领先36.9%），FENNEC PHARMACEUTICALS INC.同比增速更快（73.8% vs 12.0%）
Fennec制药是一家生物制药企业，专注于开发和商业化可降低儿童癌症患者治疗相关副作用的特种疗法，核心产品针对化疗引发的耳毒性，主要市场覆盖北美，服务肿瘤诊疗机构及儿童肿瘤患者群体。
FENC vs FVR — 直观对比
营收规模更大
FVR
是对方的1.3倍
$13.8M
营收增速更快
FENC
高出61.9%
12.0%
净利率更高
FVR
高出36.9%
-34.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.8M | $18.2M |
| 净利润 | $-4.8M | $400.0K |
| 毛利率 | — | — |
| 营业利润率 | -18.5% | 24.9% |
| 净利率 | -34.7% | 2.2% |
| 营收同比 | 73.8% | 12.0% |
| 净利润同比 | -141.1% | — |
| 每股收益（稀释后） | $-0.17 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FENCFVR
| Q1 26 | — | $18.2M | ||
| Q4 25 | $13.8M | $16.5M | ||
| Q3 25 | $12.5M | $16.8M | ||
| Q2 25 | $9.7M | $17.6M | ||
| Q1 25 | $8.8M | $16.2M | ||
| Q4 24 | $7.9M | — | ||
| Q3 24 | $7.0M | $14.5M | ||
| Q2 24 | $7.3M | — |
净利润FENCFVR
| Q1 26 | — | $400.0K | ||
| Q4 25 | $-4.8M | $-4.1M | ||
| Q3 25 | $-638.0K | $4.0M | ||
| Q2 25 | $-3.2M | $-2.9M | ||
| Q1 25 | $-1.2M | $-833.0K | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-5.7M | $-2.4M | ||
| Q2 24 | $-5.6M | — |
营业利润率FENCFVR
| Q1 26 | — | 24.9% | ||
| Q4 25 | -18.5% | — | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -28.3% | — | ||
| Q1 25 | -9.2% | — | ||
| Q4 24 | -11.8% | — | ||
| Q3 24 | -74.6% | — | ||
| Q2 24 | -69.4% | — |
净利率FENCFVR
| Q1 26 | — | 2.2% | ||
| Q4 25 | -34.7% | -24.9% | ||
| Q3 25 | -5.1% | 23.9% | ||
| Q2 25 | -32.7% | -16.5% | ||
| Q1 25 | -13.3% | -5.1% | ||
| Q4 24 | -25.0% | — | ||
| Q3 24 | -82.2% | -16.7% | ||
| Q2 24 | -76.5% | — |
每股收益（稀释后）FENCFVR
| Q1 26 | — | — | ||
| Q4 25 | $-0.17 | $-0.19 | ||
| Q3 25 | $-0.02 | $0.19 | ||
| Q2 25 | $-0.11 | $-0.16 | ||
| Q1 25 | $-0.04 | $-0.06 | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.8M | $9.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $35.5M | $514.2M |
| 总资产 | $70.6M | $869.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FENCFVR
| Q1 26 | — | $9.3M | ||
| Q4 25 | $36.8M | $13.5M | ||
| Q3 25 | $21.9M | $19.6M | ||
| Q2 25 | $18.7M | $8.4M | ||
| Q1 25 | $22.7M | $3.3M | ||
| Q4 24 | $26.6M | — | ||
| Q3 24 | $40.3M | — | ||
| Q2 24 | $43.1M | — |
总债务FENCFVR
| Q1 26 | — | — | ||
| Q4 25 | — | $314.3M | ||
| Q3 25 | $19.4M | $307.1M | ||
| Q2 25 | $19.4M | $316.9M | ||
| Q1 25 | $19.4M | $310.2M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — |
股东权益FENCFVR
| Q1 26 | — | $514.2M | ||
| Q4 25 | $35.5M | $391.2M | ||
| Q3 25 | $-4.5M | $385.2M | ||
| Q2 25 | $-7.5M | $369.9M | ||
| Q1 25 | $-5.9M | $324.7M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-5.2M | $1.0K | ||
| Q2 24 | $-1.4M | — |
总资产FENCFVR
| Q1 26 | — | $869.8M | ||
| Q4 25 | $70.6M | $854.4M | ||
| Q3 25 | $49.3M | $846.8M | ||
| Q2 25 | $44.9M | $856.5M | ||
| Q1 25 | $46.4M | $860.8M | ||
| Q4 24 | $44.9M | — | ||
| Q3 24 | $58.9M | $1.0K | ||
| Q2 24 | $63.2M | — |
负债/权益比FENCFVR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.80× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.0M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FENCFVR
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | $42.1M | ||
| Q3 25 | $1.5M | $8.3M | ||
| Q2 25 | $-3.7M | $9.3M | ||
| Q1 25 | $-4.3M | $8.1M | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-2.2M | — | ||
| Q2 24 | $-8.4M | — |
现金转化率FENCFVR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
